2023
HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma
McNamara B, Mutlu L, Greenman M, Harold J, Santin A. HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma. Cancers 2023, 15: 4085. PMID: 37627113, PMCID: PMC10452357, DOI: 10.3390/cancers15164085.Peer-Reviewed Original ResearchUterine serous carcinomaHuman epidermal growth factor receptor 2Uterine carcinosarcomaSerous carcinomaTraditional platinum-based chemotherapyEpidermal growth factor receptor 2Growth factor receptor 2Platinum-based chemotherapyOngoing clinical trialsRare histologic variantHER2 protein overexpressionAggressive metastatic potentialFactor receptor 2Distinct molecular profilesPreclinical evidenceUterine carcinomaHistologic variantsClinical trialsHER2 oncogeneReceptor 2Metastatic potentialCarcinomaMolecular profileMolecular targetsProtein overexpression
2022
Microtentacle Formation in Ovarian Carcinoma
Reader JC, Fan C, Ory EC, Ju J, Lee R, Vitolo MI, Smith P, Wu S, Ching MMN, Asiedu EB, Jewell CM, Rao GG, Fulton A, Webb TJ, Yang P, Santin AD, Huang HC, Martin SS, Roque DM. Microtentacle Formation in Ovarian Carcinoma. Cancers 2022, 14: 800. PMID: 35159067, PMCID: PMC8834106, DOI: 10.3390/cancers14030800.Peer-Reviewed Original ResearchHuman ovarian surface epitheliumOvarian cancerCell linesCancer cellsMajor therapeutic challengeIntraperitoneal drug deliveryOvarian surface epitheliumOvarian cancer metastasisNew therapeutic targetsDevelopment of chemoresistanceEffect of treatmentBreast cancer cellsOSC cell linesExtrapelvic metastasesMalignant ascitesTherapeutic challengeOvarian carcinomaSurface epitheliumTherapeutic targetMetastatic potentialAscitesCancer metastasisΒ-tubulin isotypesIndividual cancer cellsMetastasis